Display options
Cite
Jacca S, Rolih V, Quaglino E, et al. Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2. Oncoimmunology. 2015;5(3):e1082705doi: 10.1080/2162402X.2015.1082705.
Jacca, S., Rolih, V., Quaglino, E., Franceschi, V., Tebaldi, G., Bolli, E., Rosamilia, A., Ottonello, S., Cavallo, F., & Donofrio, G. (2016). Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2. Oncoimmunology, 5(3), e1082705. https://doi.org/10.1080/2162402X.2015.1082705
Jacca, Sarah, et al. "Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2." Oncoimmunology vol. 5,3 (2016): e1082705. doi: https://doi.org/10.1080/2162402X.2015.1082705
Jacca S, Rolih V, Quaglino E, Franceschi V, Tebaldi G, Bolli E, Rosamilia A, Ottonello S, Cavallo F, Donofrio G. Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2. Oncoimmunology. 2015 Aug 31;5(3):e1082705. doi: 10.1080/2162402X.2015.1082705. eCollection 2016 Mar. PMID: 27141335; PMCID: PMC4839386.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Aug 31;5(3):e1082705. doi: 10.1080/2162402X.2015.1082705. eCollection 2016 Mar.

Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2.

Oncoimmunology

Sarah Jacca, Valeria Rolih, Elena Quaglino, Valentina Franceschi, Giulia Tebaldi, Elisabetta Bolli, Alfonso Rosamilia, Simone Ottonello, Federica Cavallo, Gaetano Donofrio

Affiliations

  1. Department of Medical-Veterinary Science, University of Parma , Parma, Italy.
  2. Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino , Torino, Italy.
  3. Department of Life Sciences, Biochemistry and Molecular Biology Unit, University of Parma , Parma, Italy.

PMID: 27141335 PMCID: PMC4839386 DOI: 10.1080/2162402X.2015.1082705

Abstract

The epidermal growth factor receptor 2 (HER-2) oncogene is a major target for the immunotherapy of breast cancer. Following up to the therapeutic success achieved with Her-2-targeting monoclonal antibodies, immune-prophylactic approaches directed against Her-2 have also been investigated taking into account, and trying to overcome, Her-2 self-tolerance. Perhaps due to safety (and efficacy) concerns, the least explored anti-Her-2 active immunization strategy so far has been the one relying on viral-vectored vaccine formulations. Taking advantage of the favorable properties of bovine herpesvirus 4 (BoHV-4) in terms of safety and ease of manipulation as well as its previously documented ability to transduce and confer immunogenicity to heterologous antigens, we tested the ability of different recombinant HER-2-BoHV-4 immunogens to 8break tolerance and elicit a protective, anti-mammary tumor antibody response in HER-2 transgenic BALB-neuT mice. All the tested constructs expressed the HER-2 transgenes at high levels and elicited significant cellular immune responses in BALB/c mice upon administration via either DNA vaccination or viral infection. In BALB-neuT mice, instead, only the viral construct expressing the membrane-bound chimeric form of Her-2 protein (BoHV-4-RHuT-gD) elicited a humoral immune response that was more intense and earlier-appearing than that induced by DNA vaccination. In keeping with this observation, two administrations of BoHV-4-RHuT-gD effectively protected BALB-neuT mice from tumor formation, with 50% of vaccinated animals tumor-free after 30 weeks from immunization compared to 100% of animals exhibiting at least one palpable tumor in the case of animals vaccinated with the other BoHV-4-HER-2 constructs.

Keywords: BALB-neuT mice; BoHV-4-based vector; HER-2 antibodies; Her-2 oncogene; recombinant BoHV-4s; vaccination

References

  1. Vaccine. 2013 Aug 20;31(37):3906-14 - PubMed
  2. J Clin Invest. 2004 Mar;113(5):709-17 - PubMed
  3. J Exp Med. 1998 Aug 3;188(3):589-96 - PubMed
  4. Clin Breast Cancer. 2008 Feb;8(1):38-49 - PubMed
  5. Cancer Cell. 2008 Jan;13(1):58-68 - PubMed
  6. Expert Rev Anticancer Ther. 2007 Sep;7(9):1183-92 - PubMed
  7. Vaccine. 2011 Jan 29;29(5):867-72 - PubMed
  8. J Clin Oncol. 1992 Jul;10(7):1049-56 - PubMed
  9. Microbes Infect. 2006 Mar;8(3):898-904 - PubMed
  10. Clin Cancer Res. 2009 Feb 1;15(3):924-32 - PubMed
  11. Ann Oncol. 2003 Sep;14(9):1346-63 - PubMed
  12. Cancer Res. 2010 Jan 1;70(1):119-28 - PubMed
  13. Cancer Res. 2008 Mar 15;68(6):1979-87 - PubMed
  14. Curr Protoc Immunol. 2008 Aug;Chapter 20:Unit 20.9.1-20.9-10 - PubMed
  15. BMC Vet Res. 2013 Jan 09;9:6 - PubMed
  16. J Virol Methods. 2006 Sep;136(1-2):126-36 - PubMed
  17. PLoS One. 2014 Apr 21;9(4):e95779 - PubMed
  18. Int J Cancer. 2009 Jan 1;124(1):150-6 - PubMed
  19. Science. 1989 May 12;244(4905):707-12 - PubMed
  20. Cancer Chemother Biol Response Modif. 2005;22:769-87 - PubMed
  21. Cancer Immunol Immunother. 2010 Aug;59(8):1247-58 - PubMed
  22. Oncoimmunology. 2015 Feb 3;4(5):e1005500 - PubMed
  23. BioDrugs. 2007;21(3):145-56 - PubMed
  24. J Clin Oncol. 2007 Aug 20;25(24):3680-7 - PubMed
  25. Nature. 2003 Feb 13;421(6924):756-60 - PubMed
  26. Clin Cancer Res. 2014 Jun 1;20(11):2910-21 - PubMed
  27. J Immunother. 2003 Mar-Apr;26(2):163-70 - PubMed
  28. Cancer Immunol Immunother. 2008 Oct;57(10):1511-21 - PubMed
  29. Clin Breast Cancer. 2003 Feb;3 Suppl 4:S173-80 - PubMed
  30. Am J Vet Res. 1983 Jun;44(6):975-80 - PubMed
  31. Nucleic Acids Res. 2005 Feb 24;33(4):e36 - PubMed
  32. N Engl J Med. 2007 Jul 5;357(1):39-51 - PubMed
  33. Neuro Oncol. 2012 Mar;14(3):288-301 - PubMed
  34. Oncogene. 2000 Dec 11;19(53):6102-14 - PubMed
  35. Am J Cancer Res. 2011;1(2):255-264 - PubMed
  36. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9208-13 - PubMed
  37. J Immunol. 2006 Jun 15;176(12):7695-703 - PubMed
  38. Cancer Res. 2004 Apr 15;64(8):2858-64 - PubMed
  39. J Immunol. 2005 Apr 1;174(7):4228-36 - PubMed
  40. Int J Cancer. 2007 Feb 1;120(3):574-84 - PubMed
  41. Vaccine. 2008 Nov 11;26(48):6031-42 - PubMed
  42. BMC Biotechnol. 2007 Oct 18;7:68 - PubMed
  43. PLoS Negl Trop Dis. 2015 Jun 18;9(6):e0003850 - PubMed
  44. Vaccine. 2011 Apr 5;29(16):3074-82 - PubMed
  45. J Virol Methods. 2010 Nov;169(2):420-4 - PubMed
  46. J Exp Med. 2009 Apr 13;206(4):849-66 - PubMed
  47. Cancer J. 2007 May-Jun;13(3):141-7 - PubMed
  48. J Immunol. 2000 Nov 1;165(9):5133-42 - PubMed
  49. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 - PubMed
  50. Cancer Cell. 2004 Apr;5(4):317-28 - PubMed
  51. Science. 1988 Jun 24;240(4860):1795-8 - PubMed
  52. Cancer Res. 2010 Apr 1;70(7):2604-12 - PubMed
  53. Plant Biotechnol J. 2016 Jan;14 (1):153-9 - PubMed
  54. Hum Gene Ther. 2003 Jul 20;14(11):1117-23 - PubMed
  55. Br J Cancer. 2010 Jan 5;102(1):134-43 - PubMed
  56. Clin Cancer Res. 2006 Dec 15;12(24):7397-405 - PubMed
  57. Cancer Res. 2005 Jul 1;65(13):5953-7 - PubMed
  58. Front Oncol. 2013 May 14;3:122 - PubMed
  59. J Virol Methods. 2002 Mar;101(1-2):49-61 - PubMed
  60. PLoS One. 2013;8(1):e52758 - PubMed
  61. J Immunol. 2006 Dec 1;177(11):7626-33 - PubMed
  62. Blood. 2003 Sep 15;102(6):2138-45 - PubMed
  63. J Immunol. 2010 Apr 15;184(8):4170-7 - PubMed
  64. Cancer Res. 2006 Aug 1;66(15):7734-40 - PubMed
  65. Clin Vaccine Immunol. 2009 Nov;16(11):1675-86 - PubMed
  66. Clin Cancer Res. 2009 Mar 1;15(5):1575-84 - PubMed
  67. Nat Med. 2006 Feb;12(2):198-206 - PubMed
  68. J Transl Med. 2014 May 10;12:122 - PubMed
  69. Cell Immunol. 2006 Apr;240(2):96-106 - PubMed

Publication Types